Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5677063 | 0.92 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL10756123 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL19021269 | 0.88 | MEN1 (0.50) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL5674848 | 0.86 | MEN1 (0.50) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL5674139 | 0.86 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL5675095 | 0.86 | MEN1 (0.65) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL8047840 | 0.85 | MEN1 (0.55) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL6443337 | 0.85 | MEN1 (0.48) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL1793668 | 0.85 | MEN1 (0.48) | ALDH1A1MEN1KMT2ATP53CYP3A4 | |
| SCHEMBL10825637 | 0.82 | MEN1 (0.46) | ALDH1A1MEN1KMT2ATP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719022-A2 | NITROGEN-CONTAINING HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC Ireland Limited (IE) | 2026-04-01 | — | — | EP | disclosed |
| US-20250185505-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | UDC IRELAND LIMITED (IE) | 2025-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250185505-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | NES, NUDC, HCN2 | ALDH1A1 2145/4885MEN1 1112/4885KMT2A 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.